NASDAQ:DMAC

DiaMedica Therapeutics - DMAC Stock Forecast, Price & News

$1.33

+0.16 (+13.68%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.19
▼
$1.35
50-Day Range: $1.17
▼
$1.97
52-Week Range: $1.15
▼
$4.80

Volume: 373,266 shs
Average Volume: 57,158 shs
Market Capitalization: $35.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

DiaMedica Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 651.9% Upside
$10.00 Price Target
Short Interest: Healthy
0.43% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$276,605 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.59) to ($0.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

561st out of 1,075 stocks

Pharmaceutical Preparations Industry

259th out of 537 stocks

3.3

Analyst's Opinion

Consensus Rating
DiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, DiaMedica Therapeutics has a forecasted upside of 651.9% from its current price of $1.33.
Amount of Analyst Coverage
DiaMedica Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.43% of the float of DiaMedica Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
DiaMedica Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in DiaMedica Therapeutics has recently increased by 153.31%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
DiaMedica Therapeutics does not currently pay a dividend.
Dividend Growth
DiaMedica Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DMAC.

N/A

News and Social Media Coverage

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DiaMedica Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $276,605.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.60% of the stock of DiaMedica Therapeutics is held by insiders.
Percentage Held by Institutions
Only 27.84% of the stock of DiaMedica Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DiaMedica Therapeutics is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DiaMedica Therapeutics is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DiaMedica Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Stock News Headlines

September 23, 2022 | morningstar.com

DiaMedica Therapeutics Inc DMAC Stock Chart

September 14, 2022 | finance.yahoo.com

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

September 13, 2022 | nasdaq.com

Insiders of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) are probably glad they bought last year as their US$854k investment now stands at US$857k

September 6, 2022 | benzinga.com

DiaMedica Therapeutics to Present at Lake Street's 6th Annual Best Ideas Growth Conference

September 6, 2022 | finance.yahoo.com

DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference

August 25, 2022 | finance.yahoo.com

DiaMedica Therapeutics Inc. (DMAC)

August 10, 2022 | finance.yahoo.com

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

August 4, 2022 | finance.yahoo.com

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

July 21, 2022 | finance.yahoo.com

Thomas Von Koch Acquires Common Shares of DiaMedica Therapeutics Inc.

July 21, 2022 | finance.yahoo.com

CORRECTION: Thomas Von Koch Acquires Common Shares of DiaMedica Therapeutics Inc.

July 14, 2022 | finance.yahoo.com

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

July 7, 2022 | finance.yahoo.com

FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why

July 6, 2022 | finance.yahoo.com

DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

May 25, 2022 | finance.yahoo.com

DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022

May 7, 2022 | finance.yahoo.com

Recent gains in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) help add back some value on insider purchases worth US$630k, still down US$149k

May 4, 2022 | seekingalpha.com

DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.07

May 4, 2022 | finance.yahoo.com

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results

April 28, 2022 | finance.yahoo.com

DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

March 14, 2022 | seekingalpha.com

DiaMedica Therapeutics GAAP EPS of -$0.65 beats by $0.08

March 14, 2022 | finance.yahoo.com

DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results

March 8, 2022 | finance.yahoo.com

DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022

February 4, 2022 | finance.yahoo.com

DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans

February 2, 2022 | finance.yahoo.com

DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer

January 25, 2022 | finance.yahoo.com

DiaMedica Therapeutics to Present Research at International Stroke Conference

January 20, 2022 | nasdaq.com

DiaMedica Therapeutics Inc. Common Stock (DMAC)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Company Calendar

Last Earnings: 8/10/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DMAC
CUSIP: N/A
CIK: 1401040
Web: www.diamedica.com
Phone: (763) 312-6755
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +651.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,590,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.00%
Return on Assets: -30.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 25.50
Quick Ratio: 25.50

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.67 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: 26,440,000
Free Float: 24,962,000
Market Cap: $35.17 million
Optionable: Not Optionable
Beta: 2.08

Key Executives

Mr. Dietrich John Pauls MBA (Age 51)
Pres, CEO & Director
Comp: $684.09k

Mr. Scott B. Kellen C.A. (Age 57)
CFO & Company Sec.
Comp: $391.72k

Dr. Edward G. Calamai Ph.D.
Consulting Head of Manufacturing

Dr. Kirsten L. Gruis M.D. (Age 49)
M.S., Chief Medical Officer

Mr. Dominic R. Cundari (Age 71)
Chief Commercial Officer

Ms. Julie VanOrsdel Daves CCRP
Sr. VP of Clinical Devel. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DMAC Stock - Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings or view top-rated stocks.
What is DiaMedica Therapeutics' stock price forecast for 2022?: 3 equities research analysts have issued 1-year target prices for DiaMedica Therapeutics' shares. Their DMAC share price forecasts range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 651.9% from the stock's current price.
View analysts price targets for DMAC or view top-rated stocks among Wall Street analysts.
How have DMAC shares performed in 2022?: DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of the year. Since then, DMAC stock has decreased by 64.3% and is now trading at $1.33.
View the best growth stocks for 2022 here.
When is DiaMedica Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our DMAC earnings forecast.
How were DiaMedica Therapeutics' earnings last quarter?: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) released its earnings results on Wednesday, August, 10th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03.

What other stocks do shareholders of DiaMedica Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).
When did DiaMedica Therapeutics IPO?: (DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.
What is DiaMedica Therapeutics' stock symbol?: DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."
How do I buy shares of DiaMedica Therapeutics?: Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is DiaMedica Therapeutics' stock price today?: One share of DMAC stock can currently be purchased for approximately $1.33.
How much money does DiaMedica Therapeutics make?: DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $35.17 million. The company earns $-13,590,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.
How can I contact DiaMedica Therapeutics?: DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for the company is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com.

This page (NASDAQ:DMAC) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial